{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:37:57Z","timestamp":1793313477934,"version":"4.5.0"},"reference-count":13,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Res Paediatr"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Obesity, age and hormone imbalances including hypothyroidism and growth hormone deficiency and therapy, but not gonadotropin-releasing hormone agonist (GnRHa) therapy, have been identified as risk factors for slipped capital femoral epiphysis (SCFE). Five of 7 reported cases describe SCFE in children shortly after GnRHa therapy cessation. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We report 3 cases of SCFE that occurred in children on GnRHa therapy for the treatment of central precocious puberty (CPP) and discuss possible promoting factors. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; An otherwise healthy 8.75-year-old girl [body mass index (BMI) Z score +1.75] developed SCFE 6.75 years into GnRHa therapy for idiopathic CPP. A second girl (with a history of acute lymphoblastic leukemia requiring total body irradiation) was 10.6 years old (BMI Z score +1.06) when she developed SCFE 3.3 years into GnRHa therapy. The third case was an 8.75-year-old female with CPP secondary to a hypothalamic hamartoma (BMI Z score +1.65) who developed bilateral SCFE 5.6 years into therapy. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Increasing evidence suggests an association between GnRHa therapy for CPP and the occurrence of SCFE. We suggest that a lack of adequate sex hormone exposure at a \u2018critical period' of bone formation may result in a weakened epiphysis that becomes susceptible to slipping.<\/jats:p>","DOI":"10.1159\/000351028","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T13:36:50Z","timestamp":1374241010000},"page":"64-68","source":"Crossref","is-referenced-by-count":13,"title":["Occurrence of Slipped Capital Femoral Epiphysis in Children Undergoing Gonadotropin-Releasing Hormone Agonist Therapy for the Treatment of Central Precocious Puberty"],"prefix":"10.1159","volume":"80","author":[{"given":"Mark","family":"Inman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenden E.","family":"Hursh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati","family":"Mokashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2013,7,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0814"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2001.14.6.729"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1578-7"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7452.1353"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/01.bpo.0000217718.10728.70"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0b013e3181b769d3"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e328320acea"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/BPB.0b013e328010b73d"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-008-1033-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.2.370"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.151S047"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1783"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2004.17.3.345"}],"container-title":["Hormone Research in Paediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/351028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/351028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:22:58Z","timestamp":1745432578000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000351028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,8,1]]},"published-print":{"date-parts":[[2013,8,7]]}},"URL":"https:\/\/doi.org\/10.1159\/000351028","archive":["Portico"],"relation":{},"ISSN":["1663-2818","1663-2826"],"issn-type":[{"value":"1663-2818","type":"print"},{"value":"1663-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}